Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 1.33 below Calidi Biotherapeutics Inc 's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 107 other companies have achieved higher Quick Ratio than Calidi Biotherapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1535, from total ranking in the first quarter 2026 at 2032.

Explain Quick Ratio?
How much Cash & cash equivalents CLDI�s has?
What are CLDI�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CLDI Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-39.53 %	-29.3 %	-58.56 %	-55.15 %	-58.99 %
Y / Y Cash & cash equivalent Change	-18.73 %	-37.21 %	-41.61 %	446.92 %	531.46 %
Quick Ratio MRQ	1.33	1.73	1.42	2	0.99
CLDI's Total Ranking	# 1535	# 2032	# 1558	# 2367	# 1667
Seq. Current Liabilities Change	-15.62 %	-2.52 %	-24.22 %	-2.99 %	-1.35 %
Seq. Cash & cash equivalent Change	-35.3 %	18.41 %	-46.02 %	96.53 %	-50.01 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 108
Healthcare Sector	# 583
Overall Market	# 1731

Quick Ratio Statistics
High	Average	Low
31.37	2.32	0.01
(Sep 30 2021)		(Dec 31 2022)

Financial Statements
Calidi Biotherapeutics Inc 's Current Liabilities	$ 3 Millions	Visit CLDI's Balance sheet
Calidi Biotherapeutics Inc 's Cash & cash equivalent	$ 4 Millions	Visit CLDI's Balance sheet
Source of CLDI's Sales		Visit CLDI's Sales by Geography

Cumulative Calidi Biotherapeutics Inc 's Quick Ratio

CLDI's Quick Ratio for the trailling 12 Months

CLDI Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-49.14 %	-53.69 %	-59.44 %	-48.88 %	-35.14 %
Y / Y Cash & cash equivalent TTM Growth	-1.58 %	21.85 %	136.24 %	514.7 %	94.16 %
Quick Ratio TTM	1.66	1.52	1.6	1.41	0.86
Total Ranking TTM	# 942	# 1026	# 838	# 1278	# 1654
Seq. Current Liabilities TTM Growth	-11.55 %	-7.99 %	-21.84 %	-20.05 %	-19.47 %
Seq. Cash & cash equivalent TTM Growth	-3.55 %	-12.35 %	-11.15 %	31.02 %	19.41 %

Quick ratio ranking by company, industry and sector >> Back to CLDI Financial Strength Comparisons >> Go to Compare CLDI Quick Ratio to its Competitors

News about Calidi Biotherapeutics Inc Quick Ratio

Calidi Biotherapeutics Receives Financial Boost to Revolutionize Cancer Therapies

Calidi Biotherapeutics Secures $3 Million Investment from Dr. Ronald Rigor for Nova Cell Subsidiary Development and Oncology Pipeline Expansion
San Diego-based biotechnology company, Calidi Biotherapeutics, has announced a strategic investment of $2 million from Dr. Ronald Rigor into its newly established subsidiary, Nova Cell, Inc. This investment is intended to accelerate the development of Calidi s Adult Adipose Allogeneic (AAA) stem cell innovative programs. In addition to the investment in Nova Cell, Dr. Rigor has also invested an additional $1 million into Calidi to further bolster its oncology pipeline of assets.
With a vision to revolutionize targeted antitumor virotherapies, Calidi Biotherapeutics has been making significant strides in the field of biotechnology. By leveraging genetic engineering and the power of stem cells, the company aims to develop innovative treatments that can effectively target and eradicate cancer cells.

On the trailing twelve months basis Current Liabilities decreased faster than Calidi Biotherapeutics Inc 's average Cash & cash equivalent, this led to increase in in Calidi Biotherapeutics Inc 's Quick Ratio to 1.66, above CLDI average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 141 other companies have achieved higher Quick Ratio than Calidi Biotherapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3918.

Explain Quick Ratio?
How much Cash & cash equivalents CLDI�s has?
What are CLDI�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 142
Healthcare Sector	# 885
Within the Market	# 1535

trailing twelve months Quick Ratio Statistics
High	Average	Low
2.61	0.74	0.01
(Jun 30 2022)		(Mar 31 2023)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Entera Bio Ltd	3.50	$ 11.309 Millions	$ 3.235 Millions
Exozymes Inc	3.49	$ 5.653 Millions	$ 1.618 Millions
Acumen Pharmaceuticals Inc	3.44	$ 160.954 Millions	$ 46.848 Millions
Century Therapeutics inc	3.29	$ 49.642 Millions	$ 15.068 Millions
Adma Biologics Inc	3.26	$ 136.020 Millions	$ 41.690 Millions
Tscan Therapeutics Inc	3.23	$ 100.156 Millions	$ 30.964 Millions
Sutro Biopharma Inc	3.11	$ 164.346 Millions	$ 52.898 Millions
Editas Medicine Inc	3.09	$ 211.645 Millions	$ 68.434 Millions
Autolus Therapeutics Plc	2.93	$ 201.630 Millions	$ 68.790 Millions
Moderna Inc	2.73	$ 6,910.000 Millions	$ 2,534.000 Millions
Sana Biotechnology Inc	2.59	$ 320.990 Millions	$ 123.752 Millions
Tarsus Pharmaceuticals Inc	2.56	$ 449.690 Millions	$ 175.753 Millions
Meiragtx Holdings Plc	2.46	$ 143.166 Millions	$ 58.096 Millions
Kodiak Sciences Inc	2.39	$ 125.903 Millions	$ 52.770 Millions
Exelixis Inc	2.32	$ 839.385 Millions	$ 361.927 Millions
Precision Biosciences Inc	2.19	$ 87.549 Millions	$ 39.886 Millions
Novavax inc	2.18	$ 719.340 Millions	$ 330.574 Millions
Regenxbio Inc	2.11	$ 174.530 Millions	$ 82.621 Millions
Biocardia Inc	2.00	$ 4.117 Millions	$ 2.055 Millions
Kymera Therapeutics Inc	1.75	$ 124.477 Millions	$ 71.326 Millions
Biocryst Pharmaceuticals Inc	1.69	$ 353.279 Millions	$ 208.846 Millions
Coherus Oncology inc	1.69	$ 127.683 Millions	$ 75.510 Millions
Bio techne Corp	1.62	$ 264.712 Millions	$ 163.700 Millions
Atara Biotherapeutics Inc	1.45	$ 9.900 Millions	$ 6.847 Millions
Twist Bioscience Corporation	1.39	$ 166.839 Millions	$ 120.255 Millions
Neumora Therapeutics Inc	1.34	$ 116.834 Millions	$ 87.478 Millions
Calidi Biotherapeutics Inc	1.33	$ 4.290 Millions	$ 3.237 Millions
Passage Bio Inc	1.17	$ 24.155 Millions	$ 20.719 Millions
Mink Therapeutics Inc	1.16	$ 8.807 Millions	$ 7.569 Millions
Amgen Inc	1.07	$ 27,404.000 Millions	$ 25,502.000 Millions

Date modified: 2026-09-02T20:40:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.